After a period of speculation Pfizer has recently stepped forward with a $14-billion bid for Medivation, trouncing Sanofi and other suitors in a move designed to boost its oncology portfolio.
Pfizer announced a definitive merger agreement under which it will acquire the US biopharma (which is currently focused on developing and commercialising small molecules for oncology) for $81.50 a share in cash, to be financed with existing funds. Continue reading
Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the early stage of the disease resulted in minimal neurological disease progression and in preservation of body weight, which often declines as the disease progresses. VYNDAQEL was well tolerated with no new safety signals observed. Continue reading
Last month our CEO, Yvette Cleland, contributed her thoughts and opinions on the staff shortage crisis currently affecting the clinical research industry to a BioPharm Insight article:
The CRO industry’s acute understaffing issue is likely to become more of a burden to sponsors and CROs as trial volumes increase while recruitment stagnates, said experts. While the issue — not enough qualified, experienced clinical research staff globally — has no clear immediate fix, several industry schemes may partly alleviate specific training gaps in the long- term, they said.
On Thursday June 23rd 2016, the UK voted in tens of millions on whether the UK should remain within the European Union. The following day it was announced that the UK will be set to leave the EU with the votes swaying 51.9% for leave and 48.1% for remain, with a 72.2% turnout.
In light of the result and after reflection around this new uncertainty for UK Life Sciences Clinical Professional’s CEO Yvette Cleland has released the following statement on the matter: Continue reading
Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments.
The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages. Continue reading
Clinical data gathered for Sandoz’s biosimilar Etanercept (derived from Amgen and Pfizer’s Enbrel) was based from a “landmark” trial design in psoriasis in which over 500 patients switched from the original drug to the biosimilar.
The data from the EGALITY trial showed the Novartis unit’s biosimilar, filed in the US and EU, met primary endpoint of Psoriasis Area and Severity Index (PASI) 75 response, after 12 weeks. Continue reading
Merck and non-profit organisation International Vaccine Institute (IVI) based in Seoul, South Korea, are collaborating to develop a more robust and scalable vaccine manufacturing processes. Merck will provide funding and expertise in areas of clarification and purification under a new research agreement between the two. Continue reading
Last night Clinical Professionals, Europe’s leading life science recruiter, attended the Global Recruiter awards with hopes of winning the award for Best Innovation in Recruitment for our Life Science Training Academy, accredited by the Science Council.
We are pleased to announce we have won!
PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The biologic is designed to directly target a gastrointestinal (GI) endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1), that binds to the α4β7 integrin on lymphocytes. Continue reading
Clinical Professionals is delighted to announce that our JustGiving page is now live.
This year Clinical Professionals has embarked upon a charitable collaboration with the Arrows Group Foundation.
The Arrows Group Foundation was first created in 2014 by Adrian Treacy, Arrows Group COO and Co-Founder, after witnessing the extent of child poverty in Delhi, in particular a 3 year old girl who was homeless and alone. As a result, the foundation was created as an independent charity with the sole aim of changing the lives of many children in India like the little girl, through imparting the same opportunities for improvement with a dedicated network of volunteers and a skill development approach. Continue reading